Get the Stockscreener App
3.91
2.98%
-0.12
After Hours:
4.02
0.11
+2.81%
Vistagen Therapeutics Inc stock is traded at $3.91, with a volume of 341.46K.
It is down -2.98% in the last 24 hours and up +15.34% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$4.03
Open:
$4.1
24h Volume:
341.46K
Relative Volume:
0.58
Market Cap:
$119.96M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.9129
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+0.51%
1M Performance:
+15.34%
6M Performance:
+84.43%
1Y Performance:
+29.04%
1-Day Range:
$3.835
$4.10
1-Week Range:
$3.82
$4.39
52-Week Range:
$1.90
$4.39
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.91 | 123.64M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Will Vistagen Therapeutics Inc. stock gain from strong economyJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.July 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
Vistagen Therapeutics Inc. stock momentum explained2025 Analyst Calls & Weekly Watchlist of Top Performers - newser.com
What institutional flow reveals about Vistagen Therapeutics Inc.GDP Growth & Reliable Intraday Trade Plans - newser.com
Applying Elliott Wave Theory to Vistagen Therapeutics Inc.Quarterly Trade Review & Weekly Market Pulse Updates - newser.com
Tools to assess Vistagen Therapeutics Inc.’s risk profileWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
VistaGen Therapeutics’ (VTGN) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Published on: 2025-10-10 09:33:10 - newser.com
Using Ichimoku Cloud for Vistagen Therapeutics Inc. technicalsExit Point & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-10-10 04:25:39 - newser.com
VistaGen Therapeutics (NASDAQ:VTGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
What MACD and RSI say about Vistagen Therapeutics Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
Advanced analytics toolkit walkthrough for Vistagen Therapeutics Inc.July 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
High Stakes Ahead: Vistagen's Fasedienol Trials Could Make Or Break The Story - RTTNews
Sector ETF performance correlation with Vistagen Therapeutics Inc.July 2025 Closing Moves & High Yield Stock Recommendations - newser.com
How moving averages guide Vistagen Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - newser.com
Detecting price anomalies in Vistagen Therapeutics Inc. with AIMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Has Vistagen Therapeutics Inc. found a price floorJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com
Understanding Vistagen Therapeutics Inc.’s price movement2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Full technical analysis of Vistagen Therapeutics Inc. stockJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
Vistagen Therapeutics Inc. stock daily chart insightsJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
What’s the recovery path for long term holders of Vistagen Therapeutics Inc.Share Buyback & Verified Momentum Stock Watchlist - newser.com
How high can Vistagen Therapeutics Inc. stock go2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Vistagen Therapeutics Inc Stock Analysis and ForecastHigh Frequency Trading Trends & Access High Yield Alerts - earlytimes.in
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Tools to monitor Vistagen Therapeutics Inc. recovery probabilityWatch List & Target Return Focused Picks - newser.com
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):